Review





Similar Products

93
R&D Systems bmpr ii
Bmpr Ii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc12553006-78-3-9?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
bmpr ii - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
R&D Systems anti bmpr ii antibody
The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II <t>(BMPR-IA</t> and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody <t>and</t> <t>1:2000</t> horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.
Anti Bmpr Ii Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc12553006-79-14-16?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
anti bmpr ii antibody - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
R&D Systems human igg1 fc fusion ectodomains
The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II <t>(BMPR-IA</t> and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody <t>and</t> <t>1:2000</t> horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.
Human Igg1 Fc Fusion Ectodomains, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc11806408-161-13-19?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human igg1 fc fusion ectodomains - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
R&D Systems anti human il 2
The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II <t>(BMPR-IA</t> and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody <t>and</t> <t>1:2000</t> horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.
Anti Human Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc11066211-103-18-24?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
anti human il 2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
R&D Systems human il 2
The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II <t>(BMPR-IA</t> and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody <t>and</t> <t>1:2000</t> horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.
Human Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc11015683-110-15-19?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
human il 2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
R&D Systems mouse anti bmpr
The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II <t>(BMPR-IA</t> and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody <t>and</t> <t>1:2000</t> horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.
Mouse Anti Bmpr, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pm37591240-732-15-19?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
mouse anti bmpr - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

91
Novus Biologicals mouse anti human bmpr2
GATA6 expression is induced via <t>BMP10-BMPR2/ALK1</t> axis. ( A–F ) HPAECs were transfected with ALK1, BMPR2, Endoglin, or control scr siRNA for 48 h, and then treated with 10 ng/ml BMP10 or vehicle for 6 h for RNA isolation and 24 h for protein isolation. ( A,C,E ): GATA6 mRNA measured by qPCR. Data are means ± SE; each experiment was repeated at least three times. ( B,D,F ): GATA6 protein levels were measured by immunoblot analysis. Data are means ± SE, each experiment was repeated at least three times. Representative blots are shown. *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s test for multiple comparisons. ( G–I ) Human PAH PASMC were treated with 10 ng/ml BMP10 or vehicle ( − ) for 48 h and immunoblot analysis to detect indicated proteins was performed. Data are means ± SE from n = 4 subjects/group. *p < 0.05 by Mann Whitney U test. ( J,K ) Equal amounts of human PAH HPAEC and PASMC were plated at 6-well plates and treated with 10 ng/ml BMP10 or vehicle ( − ). 48 h later cell counts were performed. Data are means ± SE from n = 3 subjects/group, 3 technical repetitions/subject. *p < 0.05 by Mann Whitney U test. ( L,M ) HPAECs were transfected with SMAD1 siRNA, and then treated with BMP10 for 6 h. GATA6 and SMAD1 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated at least three times. *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post-hoc correction for multiple comparisons. ( N,O ) HPAEC were treated for 30 min with diluent ( − ), 5 µM ERK1/2 inhibitor SCH772984 (ERKi), or 5 µM GSK3 inhibitor CHIR99021 (GSK3i) and then stimulated with BMP10 (10 ng/ml) or vehicle for 24 h. Representative immunoblots ( N ) and statistical analysis ( O ) are shown. ( O ): Data represent GATA6/β-actin ratio. Data are means ± SE from five independent experiments. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. ( E ) HPAECs were treated with BMP10 in the presence or absence of 10 µM ERK1/2 inhibitor SCH772984 for 24 h. GATA6 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated six times. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. The original blots are presented in Supplementary Fig. .
Mouse Anti Human Bmpr2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc10122657-111-45-48?v=Novus+Biologicals
Average 91 stars, based on 1 article reviews
mouse anti human bmpr2 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

91
Novus Biologicals anti human mouse actr2b
GATA6 expression is induced via <t>BMP10-BMPR2/ALK1</t> axis. ( A–F ) HPAECs were transfected with ALK1, BMPR2, Endoglin, or control scr siRNA for 48 h, and then treated with 10 ng/ml BMP10 or vehicle for 6 h for RNA isolation and 24 h for protein isolation. ( A,C,E ): GATA6 mRNA measured by qPCR. Data are means ± SE; each experiment was repeated at least three times. ( B,D,F ): GATA6 protein levels were measured by immunoblot analysis. Data are means ± SE, each experiment was repeated at least three times. Representative blots are shown. *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s test for multiple comparisons. ( G–I ) Human PAH PASMC were treated with 10 ng/ml BMP10 or vehicle ( − ) for 48 h and immunoblot analysis to detect indicated proteins was performed. Data are means ± SE from n = 4 subjects/group. *p < 0.05 by Mann Whitney U test. ( J,K ) Equal amounts of human PAH HPAEC and PASMC were plated at 6-well plates and treated with 10 ng/ml BMP10 or vehicle ( − ). 48 h later cell counts were performed. Data are means ± SE from n = 3 subjects/group, 3 technical repetitions/subject. *p < 0.05 by Mann Whitney U test. ( L,M ) HPAECs were transfected with SMAD1 siRNA, and then treated with BMP10 for 6 h. GATA6 and SMAD1 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated at least three times. *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post-hoc correction for multiple comparisons. ( N,O ) HPAEC were treated for 30 min with diluent ( − ), 5 µM ERK1/2 inhibitor SCH772984 (ERKi), or 5 µM GSK3 inhibitor CHIR99021 (GSK3i) and then stimulated with BMP10 (10 ng/ml) or vehicle for 24 h. Representative immunoblots ( N ) and statistical analysis ( O ) are shown. ( O ): Data represent GATA6/β-actin ratio. Data are means ± SE from five independent experiments. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. ( E ) HPAECs were treated with BMP10 in the presence or absence of 10 µM ERK1/2 inhibitor SCH772984 for 24 h. GATA6 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated six times. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. The original blots are presented in Supplementary Fig. .
Anti Human Mouse Actr2b, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+bmpr-ii+antibody/pmc10122657-111-39-48?v=Novus+Biologicals
Average 91 stars, based on 1 article reviews
anti human mouse actr2b - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

Image Search Results


The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II (BMPR-IA and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody and 1:2000 horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.

Journal: Regenerative Therapy

Article Title: Bone morphogenetic protein-2-derived osteogenic peptide promotes bone regeneration via osteoblastogenesis

doi: 10.1016/j.reth.2025.09.006

Figure Lengend Snippet: The osteogenic signal transduction of OP5. (A) The binding affinity of the peptide to BMP receptor types IA and II (BMPR-IA and II). BMPR-IA or BMPR-II in lysate of human mesenchymal stromal cells (hMSCs) was immobilized on a microplate using a specific BMP receptor antibody in an ELISA. Data represents mean ± S.D. Binding activity of BMP-2 (2 μg/ml) and OP5 (20 μg/ml) are detected using anti-BMP-2 monoclonal antibody and 1:2000 horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG as a secondary antibody binding to primary antibody. Each bar shows the mean ± S.D. ∗ P < 0.05, ∗∗ P < 0.01. (B) Western blot analysis of β-catenin, phosphorylated cAMP response element-binding protein (P-CREB), and phosphorylated SMAD (P-SMAD) expression in hMSCs treated with BMP-2 and OP5 for 3 and 6 h. Cell lysates were prepared and analyzed by western blot using antibodies to β-catenin, P-CREB, and P-SMAD (all of 1:1000). The expression level of each group was normalized with the density % of β-actin in the same group. O.D., optical density; None, without peptide or protein group; BMP, bone morphogenetic protein; OP, osteogenic peptide; DWIVA, amino acid sequence from osteogenic peptide; 10F, 10F medium [Low-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic/antimycotic] as the control group.

Article Snippet: The plates were then incubated overnight at 4 °C with 1:1,000 mouse anti-BMPR-IA and anti-BMPR-II antibody (R&D systems), followed by reaction with 1:2000 horseradish peroxidase (HRP)-conjugate rabbit anti-mouse IgG (catalog no. 7076; Cell Signaling Technology Inc., Danvers, MA, USA) for 30 min at room temperature.

Techniques: Transduction, Binding Assay, Enzyme-linked Immunosorbent Assay, Activity Assay, Western Blot, Expressing, Sequencing, Modification, Control

GATA6 expression is induced via BMP10-BMPR2/ALK1 axis. ( A–F ) HPAECs were transfected with ALK1, BMPR2, Endoglin, or control scr siRNA for 48 h, and then treated with 10 ng/ml BMP10 or vehicle for 6 h for RNA isolation and 24 h for protein isolation. ( A,C,E ): GATA6 mRNA measured by qPCR. Data are means ± SE; each experiment was repeated at least three times. ( B,D,F ): GATA6 protein levels were measured by immunoblot analysis. Data are means ± SE, each experiment was repeated at least three times. Representative blots are shown. *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s test for multiple comparisons. ( G–I ) Human PAH PASMC were treated with 10 ng/ml BMP10 or vehicle ( − ) for 48 h and immunoblot analysis to detect indicated proteins was performed. Data are means ± SE from n = 4 subjects/group. *p < 0.05 by Mann Whitney U test. ( J,K ) Equal amounts of human PAH HPAEC and PASMC were plated at 6-well plates and treated with 10 ng/ml BMP10 or vehicle ( − ). 48 h later cell counts were performed. Data are means ± SE from n = 3 subjects/group, 3 technical repetitions/subject. *p < 0.05 by Mann Whitney U test. ( L,M ) HPAECs were transfected with SMAD1 siRNA, and then treated with BMP10 for 6 h. GATA6 and SMAD1 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated at least three times. *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post-hoc correction for multiple comparisons. ( N,O ) HPAEC were treated for 30 min with diluent ( − ), 5 µM ERK1/2 inhibitor SCH772984 (ERKi), or 5 µM GSK3 inhibitor CHIR99021 (GSK3i) and then stimulated with BMP10 (10 ng/ml) or vehicle for 24 h. Representative immunoblots ( N ) and statistical analysis ( O ) are shown. ( O ): Data represent GATA6/β-actin ratio. Data are means ± SE from five independent experiments. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. ( E ) HPAECs were treated with BMP10 in the presence or absence of 10 µM ERK1/2 inhibitor SCH772984 for 24 h. GATA6 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated six times. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. The original blots are presented in Supplementary Fig. .

Journal: Scientific Reports

Article Title: GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension

doi: 10.1038/s41598-023-33779-8

Figure Lengend Snippet: GATA6 expression is induced via BMP10-BMPR2/ALK1 axis. ( A–F ) HPAECs were transfected with ALK1, BMPR2, Endoglin, or control scr siRNA for 48 h, and then treated with 10 ng/ml BMP10 or vehicle for 6 h for RNA isolation and 24 h for protein isolation. ( A,C,E ): GATA6 mRNA measured by qPCR. Data are means ± SE; each experiment was repeated at least three times. ( B,D,F ): GATA6 protein levels were measured by immunoblot analysis. Data are means ± SE, each experiment was repeated at least three times. Representative blots are shown. *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s test for multiple comparisons. ( G–I ) Human PAH PASMC were treated with 10 ng/ml BMP10 or vehicle ( − ) for 48 h and immunoblot analysis to detect indicated proteins was performed. Data are means ± SE from n = 4 subjects/group. *p < 0.05 by Mann Whitney U test. ( J,K ) Equal amounts of human PAH HPAEC and PASMC were plated at 6-well plates and treated with 10 ng/ml BMP10 or vehicle ( − ). 48 h later cell counts were performed. Data are means ± SE from n = 3 subjects/group, 3 technical repetitions/subject. *p < 0.05 by Mann Whitney U test. ( L,M ) HPAECs were transfected with SMAD1 siRNA, and then treated with BMP10 for 6 h. GATA6 and SMAD1 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated at least three times. *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post-hoc correction for multiple comparisons. ( N,O ) HPAEC were treated for 30 min with diluent ( − ), 5 µM ERK1/2 inhibitor SCH772984 (ERKi), or 5 µM GSK3 inhibitor CHIR99021 (GSK3i) and then stimulated with BMP10 (10 ng/ml) or vehicle for 24 h. Representative immunoblots ( N ) and statistical analysis ( O ) are shown. ( O ): Data represent GATA6/β-actin ratio. Data are means ± SE from five independent experiments. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. ( E ) HPAECs were treated with BMP10 in the presence or absence of 10 µM ERK1/2 inhibitor SCH772984 for 24 h. GATA6 mRNA levels were measured by qPCR. Data shown as means ± SE. Each experiment was repeated six times. *p < 0.05 by Kruskal–Wallis test with post-hoc Dunn’s correction for multiple comparisons. The original blots are presented in Supplementary Fig. .

Article Snippet: Antibodies were as follows: Goat anti-human GATA6 (R&D; AF1700, 1:500), mouse anti-human GATA6 (Santa-Cruz, 517554, 1:500), Rabbit anti-human/mouse SOD2 (Cell signaling technology; 13141, 1:1000; 13145, 1:5000), Goat anti-human ALK1 (R&D; AF370, 1:500), Rabbit anti-mouse ALK1 (ABGENT AP7807a, 1:1000), rabbit anti-human/mouse ActR2B (LS bio; LS-B7781, 1:1000), mouse anti-human BMPR2 (Novus; NBP2-37624 Clone 3F6; 1:1000), rabbit anti-mouse BMPR2 (Proteintech; 19087–1-AP; 1:1000), mouse anti-mouse/human/rat BMPR2 (Abcam, catalog #130206 1:500), rabbit anti-human/mouse Endoglin (Proteintech; 10862–1-AP; 1:1000), rabbit anti-mouse BiP (Abcam; ab53068; 1:1000), rabbit anti-mouse CHOP (Novus; NBP2-13172; 1:1000), mouse anti-beta-actin (Sigma; A1978; 1:2000), mouse anti-human PRPF4 (Abcam, 69878, 1:1000), rabbit anti-human MYEOV (Invitrogen, PA5-48938 1:1000), rabbit anti-human STING (Invitrogen, PA5-26751, 1:1000), rabbit anti-human/mouse/rat EAF1 (Invitrogen, PA5-100493, 1:1000), rabbit anti-human/mouse/rat Histone H3 (Cell Signaling, 9715 1:1000), rabbit anti-human/mouse/rat a-b Tubulin (Cell Signaling, 2148, 1:1000).

Techniques: Expressing, Transfection, Control, Isolation, Western Blot, MANN-WHITNEY

GATA6 deficiency in PAEC and PASMC results in loss of BMP receptors. ( A ) qPCR of HPAECs transfected with GATA6 or control scr siRNA ( − ) to measure indicated mRNA, each experiment was repeated at least three times. Data are means ± SE, n = 4–7. **p < 0.01, ***p < 0.001 by Mann Whitney U test. ( B ) Chromatin immune precipitation (ChiP) assay in HPAECs, n = 8–10. Representative gel images and data quantification are shown. Data are means ± SE, ***p < 0.001, ****p < 0.0001 by Mann Whitney U test. ( C,D ) Immunoblot analysis of control human PASMC transfected with siRNA GATA6 or control scr siRNA for 48 h. Data are means ± SE, 3 subjects/group, *p < 0.05 by Mann Whitney U test. Please see Fig. F,G for GATA6 immunoblots. ( E,F ) Expression of BmpR2, Alk1 , ActRIIB, and endoglin measured by qPCR in PAEC ( F ) and whole lungs ( G ) from WT and Gata6 CKO mice. Data are means ± SE; E: n = 4–5/group; F: n = 6–11 mice/group. Male and female mice responded similarly. *p < 0.05, **p < 0.01 by Mann Whitney U test (( E,F ) BmpR2, Alk1 , and ActRIIB ) and unpaired τ test (F Endoglin ). ( G,H ) Control HPAECs transfected with siGATA6 or control scr siRNA ( − ) were assayed by immunoblot analysis to detect indicated BMP receptors. Values are means ± SE of the relative protein levels by densitometry, n = 4–7.*p < 0.05, ***p < 0.001 by Mann Whitney U test. ( I,J ) Immunoblot analysis of whole lung tissue from Gata6 CKO and WT mice. Values are means ± SE of the relative protein levels by densitometry, n = 3–5/group. Male and female mice responded similarly. *p < 0.05, **p < 0.01 by Mann Whitney U test. The original blots are presented in Supplementary Fig. .

Journal: Scientific Reports

Article Title: GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension

doi: 10.1038/s41598-023-33779-8

Figure Lengend Snippet: GATA6 deficiency in PAEC and PASMC results in loss of BMP receptors. ( A ) qPCR of HPAECs transfected with GATA6 or control scr siRNA ( − ) to measure indicated mRNA, each experiment was repeated at least three times. Data are means ± SE, n = 4–7. **p < 0.01, ***p < 0.001 by Mann Whitney U test. ( B ) Chromatin immune precipitation (ChiP) assay in HPAECs, n = 8–10. Representative gel images and data quantification are shown. Data are means ± SE, ***p < 0.001, ****p < 0.0001 by Mann Whitney U test. ( C,D ) Immunoblot analysis of control human PASMC transfected with siRNA GATA6 or control scr siRNA for 48 h. Data are means ± SE, 3 subjects/group, *p < 0.05 by Mann Whitney U test. Please see Fig. F,G for GATA6 immunoblots. ( E,F ) Expression of BmpR2, Alk1 , ActRIIB, and endoglin measured by qPCR in PAEC ( F ) and whole lungs ( G ) from WT and Gata6 CKO mice. Data are means ± SE; E: n = 4–5/group; F: n = 6–11 mice/group. Male and female mice responded similarly. *p < 0.05, **p < 0.01 by Mann Whitney U test (( E,F ) BmpR2, Alk1 , and ActRIIB ) and unpaired τ test (F Endoglin ). ( G,H ) Control HPAECs transfected with siGATA6 or control scr siRNA ( − ) were assayed by immunoblot analysis to detect indicated BMP receptors. Values are means ± SE of the relative protein levels by densitometry, n = 4–7.*p < 0.05, ***p < 0.001 by Mann Whitney U test. ( I,J ) Immunoblot analysis of whole lung tissue from Gata6 CKO and WT mice. Values are means ± SE of the relative protein levels by densitometry, n = 3–5/group. Male and female mice responded similarly. *p < 0.05, **p < 0.01 by Mann Whitney U test. The original blots are presented in Supplementary Fig. .

Article Snippet: Antibodies were as follows: Goat anti-human GATA6 (R&D; AF1700, 1:500), mouse anti-human GATA6 (Santa-Cruz, 517554, 1:500), Rabbit anti-human/mouse SOD2 (Cell signaling technology; 13141, 1:1000; 13145, 1:5000), Goat anti-human ALK1 (R&D; AF370, 1:500), Rabbit anti-mouse ALK1 (ABGENT AP7807a, 1:1000), rabbit anti-human/mouse ActR2B (LS bio; LS-B7781, 1:1000), mouse anti-human BMPR2 (Novus; NBP2-37624 Clone 3F6; 1:1000), rabbit anti-mouse BMPR2 (Proteintech; 19087–1-AP; 1:1000), mouse anti-mouse/human/rat BMPR2 (Abcam, catalog #130206 1:500), rabbit anti-human/mouse Endoglin (Proteintech; 10862–1-AP; 1:1000), rabbit anti-mouse BiP (Abcam; ab53068; 1:1000), rabbit anti-mouse CHOP (Novus; NBP2-13172; 1:1000), mouse anti-beta-actin (Sigma; A1978; 1:2000), mouse anti-human PRPF4 (Abcam, 69878, 1:1000), rabbit anti-human MYEOV (Invitrogen, PA5-48938 1:1000), rabbit anti-human STING (Invitrogen, PA5-26751, 1:1000), rabbit anti-human/mouse/rat EAF1 (Invitrogen, PA5-100493, 1:1000), rabbit anti-human/mouse/rat Histone H3 (Cell Signaling, 9715 1:1000), rabbit anti-human/mouse/rat a-b Tubulin (Cell Signaling, 2148, 1:1000).

Techniques: Transfection, Control, MANN-WHITNEY, Western Blot, Expressing

Treatment with DMF restores expression of the BMP receptors, reverses oxidative stress and pulmonary hypertension in Gata6 CKO mice. (DMF or vehicle were administered daily via i.p. injection for 3 weeks. ( A ) qPCR analysis of whole lung tissue from WT and Gata6 CKO mice treated with DMF or vehicle to detect expression of indicated BMP receptors. Data are means ± SE, n = 6–12, *p < 0.05. **p < 0.01 by Kruskal–Wallis test followed by Dunn’s multiple comparisons test ( BmpR2, ActRIIB, Alk1 ) and one-way ANOVA followed by post hoc Tukey’s multiple comparison ( Endoglin ). ( B ) qPCR analysis of whole lung tissue from WT and Gata6 CKO mice treated with DMF or vehicle to detect expression of the antioxidant enzymes and eNOS . Data are means ± SE, n = 6–17, *p < 0.05., **p < 0.01, ***p < 0.001 by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test ( SOD2, GPX1, CAT ) and Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test ( eNOS ). ( C,D ) mRNA levels of indicated BMP receptors and antioxidant enzymes measured by qPCR in PAEC from WT and Gata6 CKO mice treated with DMF or vehicle. Data are means ± SE, n = 3–6 mice/group, *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test. ( E–G ) RVSP, pulmonary acceleration time as a fraction of ejection time (PAT/ET) and Fulton index (RV/[LV + S]) were evaluated in WT and Gata6 CKO mice in the presence or absence of DMF. Data are means ± SE. n = 5–11 mice/group. *p < 0.05, **p < 0.01. ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test (RVSP) and one-way ANOVA followed by post hoc Tukey’s multiple comparisons test (PAT/ET and RV/(LV + S).

Journal: Scientific Reports

Article Title: GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension

doi: 10.1038/s41598-023-33779-8

Figure Lengend Snippet: Treatment with DMF restores expression of the BMP receptors, reverses oxidative stress and pulmonary hypertension in Gata6 CKO mice. (DMF or vehicle were administered daily via i.p. injection for 3 weeks. ( A ) qPCR analysis of whole lung tissue from WT and Gata6 CKO mice treated with DMF or vehicle to detect expression of indicated BMP receptors. Data are means ± SE, n = 6–12, *p < 0.05. **p < 0.01 by Kruskal–Wallis test followed by Dunn’s multiple comparisons test ( BmpR2, ActRIIB, Alk1 ) and one-way ANOVA followed by post hoc Tukey’s multiple comparison ( Endoglin ). ( B ) qPCR analysis of whole lung tissue from WT and Gata6 CKO mice treated with DMF or vehicle to detect expression of the antioxidant enzymes and eNOS . Data are means ± SE, n = 6–17, *p < 0.05., **p < 0.01, ***p < 0.001 by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test ( SOD2, GPX1, CAT ) and Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test ( eNOS ). ( C,D ) mRNA levels of indicated BMP receptors and antioxidant enzymes measured by qPCR in PAEC from WT and Gata6 CKO mice treated with DMF or vehicle. Data are means ± SE, n = 3–6 mice/group, *p < 0.05, **p < 0.01 by Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test. ( E–G ) RVSP, pulmonary acceleration time as a fraction of ejection time (PAT/ET) and Fulton index (RV/[LV + S]) were evaluated in WT and Gata6 CKO mice in the presence or absence of DMF. Data are means ± SE. n = 5–11 mice/group. *p < 0.05, **p < 0.01. ***p < 0.001 by Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test (RVSP) and one-way ANOVA followed by post hoc Tukey’s multiple comparisons test (PAT/ET and RV/(LV + S).

Article Snippet: Antibodies were as follows: Goat anti-human GATA6 (R&D; AF1700, 1:500), mouse anti-human GATA6 (Santa-Cruz, 517554, 1:500), Rabbit anti-human/mouse SOD2 (Cell signaling technology; 13141, 1:1000; 13145, 1:5000), Goat anti-human ALK1 (R&D; AF370, 1:500), Rabbit anti-mouse ALK1 (ABGENT AP7807a, 1:1000), rabbit anti-human/mouse ActR2B (LS bio; LS-B7781, 1:1000), mouse anti-human BMPR2 (Novus; NBP2-37624 Clone 3F6; 1:1000), rabbit anti-mouse BMPR2 (Proteintech; 19087–1-AP; 1:1000), mouse anti-mouse/human/rat BMPR2 (Abcam, catalog #130206 1:500), rabbit anti-human/mouse Endoglin (Proteintech; 10862–1-AP; 1:1000), rabbit anti-mouse BiP (Abcam; ab53068; 1:1000), rabbit anti-mouse CHOP (Novus; NBP2-13172; 1:1000), mouse anti-beta-actin (Sigma; A1978; 1:2000), mouse anti-human PRPF4 (Abcam, 69878, 1:1000), rabbit anti-human MYEOV (Invitrogen, PA5-48938 1:1000), rabbit anti-human STING (Invitrogen, PA5-26751, 1:1000), rabbit anti-human/mouse/rat EAF1 (Invitrogen, PA5-100493, 1:1000), rabbit anti-human/mouse/rat Histone H3 (Cell Signaling, 9715 1:1000), rabbit anti-human/mouse/rat a-b Tubulin (Cell Signaling, 2148, 1:1000).

Techniques: Expressing, Injection, Comparison